I, and others on this board, have commented about the many indications AVXL 2-73 seems to have. If this continues to prove to be the case, it increases the chances of FDA approval for some of those indications, which means it will be used off label for other indications. I have also commented in the past about how most everything the FDA does takes longer than most expect or hope. Of course, FDA processes have been accelerated over the years, but It is still a government bureaucracy. Furthermore, the FDA is dealing with new FDA procedures here in the way the Anavex clinical trials are designed and implemented.
And yes, Missling did make mistakes about how long it would be for these trails to be approved and commenced, but that does not change anything about the science, indications and potential for the drug to be a success. Shareholders that sold yesterday at the price of $1.85 are the ones that made the big mistake in my opinion. However, we are all human. We all make mistakes. Being overly optimistic is sometimes a human mistake as is being overly pessimestic, or for capitulating and dumping your investment at precisely the wrong time.
History does repeat itself. It repeats itself because we are all human with the same characteristic, traits, and emotions no matter of what generation. Missling has made mistakes, but those mistakes are not as grave as some may make them out to be. Humans have overacted to the mistakes he made, but in the end those mistakes will be forgotten and forgiven because that is what humanity does.
Market Data 
Markets 
AI
